ELISA HLA-DRA anti-
Quantity :50µg
Clone Number:
Aliases:DASS-397D15.1 antibody; DR alpha chain antibody; DR alpha chain precursor antibody; DRA_ antibody; DRB1 antibody; DRB4 antibody; FLJ51114 antibody; Histocompatibility antigen HLA DR alpha antibody; Histocompatibility antigen HLA-DR alpha antibody; HLA class II histocompatibility antigen antibody; HLA class II histocompatibility antigen DR alpha chain antibody; HLA DR1B antibody; HLA DR3B antibody; HLA DRA antibody; HLA DRA1 antibody; HLA DRB1 antibody; HLA DRB3 antibody; HLA DRB4 antibody; HLA DRB5 antibody; HLA-DR histocompatibility type antibody; HLA-DRA antibody; HLADR4B antibody; HLADRA1 antibody; HLADRB antibody; Major histocompatibility complex class II DR alpha antibody; Major histocompatibility complex class II DR beta 1 antibody; Major histocompatibility complex class II DR beta 3 antibody; Major histocompatibility complex class II DR beta 4 antibody; Major histocompatibility complex class II DR beta 5 antibody; MGC117330 antibody; MHC cell surface glycoprotein antibody; MHC class II antigen DRA antibody; MHC II antibody; mLRW antibody; OTTHUMP00000029406 antibody; OTTHUMP00000029407 antibody
Product Type:Polyclonal Antibody
Immunogen Species:Homo sapiens ()
UniProt ID:P01903
Immunogen:Recombinant HLA class II histocompatibility antigen, DR alpha chain protein (28-254AA)
Raised in:Rabbit
Reactivity:
Tested Applications:ELISA, IHC; Recommended dilution: IHC:1:20-1:200
Background:Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecµLes are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecµLes, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecµLes and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecµLe that presents an antigen, three MHC class II molecµLes (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecµLes until primary high affinity antigenic peptides are bound. The MHC II molecµLe bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecµLes is regµLated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regµLation of antigen loading into MHC II molecµLes, increased acidification produces increased proteolysis and efficient peptide loading.
Clonality:Polyclonal
Isotype:IgG
Purification Method:>95%, Protein G purified
Conjµgate:Non-conjµgated
Buffer:Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form:Liquid
Stroage:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Target Names:HLA-DRA
Research Areas:Immunology